Nona Biosciences and OverT Bio have joined forces to develop cutting-edge cell therapies for solid tumors. This strategic collaboration leverages Nona’s fully human HCAb technology and OverT Bio’s innovative genetic enhancements, aiming to deliver transformative therapies for patients.